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Objective
To estimate the cost-effectiveness of surveillance schedules
for non-muscle-invasive bladder cancer (NMIBC) amongst
older adults.
Patients and Methods
We developed a MIcrosimulation SCreening ANalysis
(MISCAN) microsimulation model to compare the cost-
effectiveness of various surveillance schedules (every 3 months
to every 24 months, for 2, 5 or 10 years or lifetime) for older
adults (aged 65–85 years) with NMIBC. For each surveillance
schedule we calculated total costs per patient and the number
of quality adjusted life-years (QALYs) gained. Incremental
cost-effectiveness ratios (ICERs), as incremental costs per
QALY gained, were calculated using a 3% discount.
Results
As age increased, the number of QALYs gained per patient
decreased substantially. Surveillance of patients aged 65 years
resulted in 2–7 QALYs gained, whereas surveillance at age
85 years led to <1 QALY gained. The total costs of the
surveillance schedules also decreased as age increased. The
ICER of 6-monthly surveillance at age 65 years for lifetime
was $4999 (American dollars)/QALY gained. Amongst
patients aged >75 years, the incremental yield of QALY gains
for any increase in surveillance frequency and/or duration
was quite modest (<2 QALYs gained).
Conclusion
With increasing age, surveillance for recurrences leads to
substantially fewer QALYs gained. These data support age-
speciﬁc surveillance recommendations for patients treated for
NMIBC.
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Introduction
About 75% of all bladder cancer diagnoses are non-muscle-
invasive bladder cancer (NMIBC) [1]. NMIBC is generally
treated surgically by transurethral resection (TUR). The 10-
year cancer-speciﬁc survival is relatively high, ranging from
70% to 85% for high-grade to 88–98% for low-grade cancers
[2,3]. However, the probability of recurrence is high (up to
75%) and 10–20% can progress to muscle-invasive bladder
cancer (MIBC), which is potentially lethal [2,4–6]. Therefore,
surveillance by cystoscopy is offered to patients with a history
of NMIBC to facilitate early diagnosis and treatment before
progression.
All international guidelines on the management of NMIBC
recommend cystoscopy at regular intervals, generally based
on the patient’s risk, but the recommended intervals differ
[7]. The AUA and the European Association of Urology
(EAU) recommend low-risk patients to have two cystoscopies
in the ﬁrst year, followed by annual cystoscopy for 5 years.
The EAU recommends discontinuing surveillance after
5 years, whereas the AUA recommends shared decision-
making to stop or continue annual surveillance [8,9]. The
National Institute for Health and Care Excellence (NICE)
guideline recommends surveillance only at 3 and 12 months
for low-risk patients, discharging low-risk patients to primary
care if recurrence-free at 12 months [10]. For high-grade
patients, various guidelines generally recommend surveillance
every 3 months for the ﬁrst 2 years, followed by every
6 months for 2 or 3 years, followed by annual and even
lifelong surveillance.
Surveillance cystoscopy is an invasive procedure. Patients may
experience anxiety and pain, or complications such as painful
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urination and UTI, which inﬂuence quality of life (QoL)
[11,12]. Furthermore, bladder cancer is largely a disease of
older adults, and has the highest median patient age at
diagnosis (73 years) of all cancer sites [13,14]. Despite
relatively stable age-adjusted incidence rates, the overall
burden of bladder cancer has increased dramatically with the
ageing of the population, increasing from stable ﬁgures of
~50 000 cases/year in the USA in the 1990s to >80 000 cases/
year projected for 2018 [15,16]. Over this same period, the
median age at diagnosis of bladder cancer has increased from
67 to 73 years.
Given substantial competing causes of death in this
predominantly elderly population, the intensity and duration
of the surveillance programme should be evaluated for
different age groups. Surveillance programmes should be
optimised in terms of frequency of cystoscopy and duration
of the surveillance, to simultaneously maximise the life-years
gained and minimise the harms and the costs.
The present study objective was to determine the most cost-
effective surveillance protocol for older adults with NMIBC.
We evaluated surveillance strategies of varying frequency and
duration.
Patients and Methods
MIcrosimulation SCreening ANalysis (MISCAN)
model
We developed a microsimulation model using the MISCAN
framework to simulate the impact of surveillance on survival
in a patient with NMIBC. MISCAN is a microsimulation
model developed for the evaluation of screening and has been
used previously to estimate the harms, beneﬁts and cost-
effectiveness of breast, colorectal, cervical and prostate cancer
screening [17–20]. In this model, individual life histories of
patients are simulated by modelling the transitions between
possible health states (Fig. 1). All patients start in the no
bladder cancer state after having been diagnosed and treated
for bladder cancer. Some patients will have a NMIBC
recurrence, which will be treated by TUR, or will progress to
the MIBC state. An assumption in the model is that
progression can only take place after recurrence. MIBC is
assumed to be treated with cystectomy, which ends
surveillance. In each subsequent state, there is an increasing
risk of death from bladder cancer, therefore preventing
progression to the MIBC state by surveillance using
cystoscopy will decrease the risk of death and will increase
the number of quality adjusted life-years (QALYs).
Model inputs were drawn from a previously developed
Markov model with time steps of 3 months [21]. This semi-
Markov model was based on the Dutch Cost-Effectiveness of
Follow-up of Urinary Bladder Cancer (CEFUB) trial, which
included 448 patients with non-muscle-invasive urothelial
cancer (NMI-UC) [22]. In that trial, the efﬁcacy of
microsatellite analysis on voided urine for detecting tumour
recurrences in the follow-up of patients was evaluated.
Patients included had a primary or recurrent NMI-UC [pTa
(85%), pT1 (15%), Grade 1 (43%) or Grade 2 (57%)] of the
urinary bladder, based on histopathological examination of
the surgically removed tumour. About half of the cohort
(118/228) was newly diagnosed, whereas the remainder was
enrolled at the time of recurrence (45 at ﬁrst recurrence, 30
at second recurrence, 16 at third recurrence, 19 at the fourth
or more recurrence). The probability of bladder cancer death
by time after progression is calibrated to data from the Dutch
Cancer Registry [21]. The probability of other causes of death
is based on the USA life table for 2010 for the general
population. The parameters used in the MISCAN model are
described in Table 1 [21, 23].
Screening strategies
We used MISCAN to simulate ﬁve cohorts of 1 million
patients aged 65, 70, 75, 80 and 85 years at diagnosis and
start of surveillance. To each cohort we applied 16
surveillance protocols, which comprised all combinations of
TUR
Cystectomy
Progression
Recurrence
No bladder cancer
No bladder
Death
NMIBC
MIBC
Fig. 1 Possible transitions in the MISCAN model.
Table 1 The parameters used in the MISCAN model, based on de Bekker-
Grob et al. [21] and Zhang et al. [23]
Parameter Value
Recurrence time, years, mean 4.18 (exponential distribution)
Time until progression, years, mean 1.46 (exponential distribution)
Time until death after progression, years, mean 2.57
Sensitivity cystoscopy, % 98
Speciﬁcity cystoscopy, % 88
Costs of cystoscopy, $ 168
Costs of TUR (after recurrence), $ 1409
Costs of cystectomy (after progression), $ 7997
Disutility of cystoscopy 0.025 for 1 month
Disutility of TUR 0.03 for 1 month
Utility in NMIBC 0.94
Utility in MIBC 0.80 for lifetime
$, American dollars.
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frequencies of 3 months, 6 months, 12 months or 24 months
and surveillance durations of 2, 5 and 10 years, or lifetime: 80
surveillance protocols with variable age of diagnosis, intensity
and duration were investigated, assuming 100% attendance to
surveillance.
Cost-effectiveness
For each surveillance protocol, we calculated the number of
cystoscopies, recurrences, progressions, and QALYs gained for
a lifetime horizon. The utility estimates to calculate QALYs
were based on Zhang et al. [23]. The total costs of each
surveillance protocol were calculated using cystoscopy and
intervention costs (TUR and cystectomy) from the literature
[21]. We used incremental cost-effectiveness ratios (ICERs) as
the ratio of incremental costs to incremental life-years gained.
An annual discount of 3% was used, and the threshold for
the ICER was set on $100 000 (American dollars).
Sensitivity analysis
We performed one-way sensitivity analyses, in which we
varied the comorbidity status, disutilities, and costs.
Comorbidity status was based on the life tables for the USA
population having no comorbidity and severe comorbidity
[24]. The disutility of cystoscopy and TUR were increased to
0.1 for 1 month and the costs for cystoscopy, TUR and
cystectomy were all lowered by 10%.
Results
The discounted QALYs gained per patient vs costs per patient
are presented for all simulated surveillance scenarios in Fig. 2.
The younger the patient was when entering a surveillance
programme, the more QALYs gained. The duration of
surveillance increased both QALYs gained and the associated
costs. However, the difference in QALYs gained between a
surveillance protocol running for 10 years and one running
for a lifetime decreased as patients aged and was negligible
for patients aged >80 years: e.g., screening every 3 months for
10 years or lifetime both resulted in 0.92 QALY gained
amongst 85-year olds and ~1.7 QALYs amongst individuals
aged 80 years. The frequency of a surveillance protocol had a
similar effect across starting ages.
In Table 2 only the cost-effective strategies within each
cohort are presented. Surveillance strategies that allow for
more surveillance (in both ways – by more frequent
cystoscopy or by longer monitoring) resulted in larger cost
increases. The number of diagnosed recurrences increased
with the number of cystoscopies. In contrast, the overall
number of diagnosed cancer progressions followed a parabolic
trend, where it increased with the duration of the surveillance
protocol but started to decrease when more than one test per
year was performed. This suggests that frequent surveillance
can detect recurrences before they progress to muscle
invasion. Detecting recurrences has a major effect on the
costs of a protocol, as the treatment of progression is over
ﬁve-times as expensive as treatment for NMIBC.
For example, 12-monthly surveillance from the age of
65 years is expected to result in 6.60 QALYs gained per
patient (without discount), whilst 6-monthly surveillance
from the same age gained an extra 0.52 QALYs at an
increased cost of $10 050/patient. The corresponding ICER
was $4999 (using a 3% discount). This small effect is
achieved by more than doubling the number of surveillance
cystoscopies.
The sensitivity analyses showed that the results were robust
to the parameters varied (Appendix S1). Only in a few cases,
a different strategy was amongst the cost-effective strategies.
Comorbidity status had the largest, although still limited,
impact on the results.
Discussion
Our present ﬁndings suggest that cystoscopy-based
surveillance for NMIBC is cost-effective for younger patients.
However, we found that, even in the youngest cohort
(65 years), lifelong quarterly cystoscopy was associated with
high-costs for modest potential QALY gains. Perhaps more
importantly, within the context of the high, and increasing,
median age at bladder cancer diagnosis, we found that the
incremental yield of QALY gains for any increase in
surveillance frequency and/or duration amongst patients aged
≥75 years was modest. Given the changing age structure of
the population and the disproportionately high incidence
rates in the oldest ages [25], the burden of bladder cancer in
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Fig. 2 The costs and QALYs gained per patient of all evaluated
surveillance strategies. Both costs and QALYs are discounted. The colours
of the symbols represent the ages at the start of the surveillance strategy
and the symbols the different frequencies of surveillance (square every
3 months, diamond every 6 months, triangle every 12 months, and circle
every 24 months).
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the elderly is projected to increase by 54% in the next
15 years [26], underscoring the public health impact of these
ﬁndings.
In contrast to other urological cancers, in particular prostate
cancer [27], age and competing risks have not, to date, been
explicitly considered in bladder cancer guidelines. A
multidisciplinary stakeholder group of clinicians, patients,
payers and patient advocates identiﬁed cancer care for the
elderly and post-treatment surveillance as two of the top
three cancers comparative effectiveness research priorities
[28]. Post-treatment surveillance for NMIBC is uniquely
invasive, intensive, and under current recommendations often
lifelong. Given the rapidly growing and ageing population of
patients with bladder cancer, it is critically important to
deﬁne age-based surveillance schedules for this group.
There are two other studies that evaluated different
surveillance protocols. Overall, the results were comparable:
for younger patients an intensive surveillance strategy was
more cost-effective than for older patients. The analysis of
Zhang et al. [23] focused on low-grade NMIBC, which
accounts for about two-thirds of all NMIBCs. International
guidelines for surveillance were simulated and the number of
cystoscopies and the QALYs were calculated for men and
women separately. The authors concluded that patient-
speciﬁc factors such as the presence of comorbidity, or
perception of utility loss from cystoscopy, should play an
important role in determining the best surveillance protocol.
Kent et al. [29] calculated the expected delay in detection of
the next tumour based on several surveillance scenarios and
concluded that the optimal surveillance schedule is less
frequent for low-risk patients than for high-risk patients. In
our present study, we considered the full spectrum of
NMIBC, including the relatively higher risk subset with
multiple recurrences, in contrast to Zhang et al. [23], and
found relatively small incremental beneﬁts of QALYs gained
for more intensive or lengthy surveillance programmes
amongst patients aged ≥75 years. As a result of advanced
chronological age, patients with bladder cancer have a high
burden of multiple chronic conditions [30] and the American
Society for Clinical Oncology has called for more explicit
consideration of these factors in the guideline development
process [31]. A previous analysis found that in patients with
the highest rates of comorbidity, the optimal surveillance
protocol was no surveillance [23]. In our present analysis,
even for patients with severe comorbidity surveillance could
still be cost-effective.
Strong points of the present study are that we included
lifetime surveillance and evaluated the results over a lifetime
horizon. Furthermore, we applied cost-effectiveness analysis
Table 2 Effects and costs (in American dollars) of the cost-effective strategies per age cohort. The number of screens, recurrences and progression,
costs and QALYs gained are given per patient over a lifetime, without discount. In the calculation of the ICER a 3% discount rate was used.
Start age, years Frequency, months Duration, years Screens, n Recurrence, n Progression, n Costs, $ QALYs ICER, $
65 24 2 0.91 0.17 0.11 1 264 1.87 920
65 24 5 2.46 0.39 0.26 3 050 3.99 1 123
65 12 5 4.51 0.55 0.19 3 017 3.86 1 145
65 12 10 8.14 0.87 0.30 4 984 5.60 1 450
65 12 Lifetime 14.34 1.19 0.41 7 374 6.60 2 786
65 6 Lifetime 30.01 1.78 0.31 10 050 7.12 4 999
65 3 Lifetime 60.59 2.27 0.20 14 973 7.29 24 758
70 12 2 1.86 0.25 0.08 1 329 1.53 1 112
70 12 5 4.36 0.53 0.18 2 924 2.98 1 445
70 12 10 7.66 0.82 0.28 4 709 4.15 2 177
70 12 Lifetime 11.66 1.05 0.36 6 327 4.62 4 579
70 6 Lifetime 24.49 1.54 0.27 8 429 5.06 4 675
70 3 Lifetime 49.65 1.92 0.17 12 405 5.22 20 195
75 12 2 1.81 0.24 0.08 1 288 1.13 1 410
75 12 5 4.13 0.50 0.17 2 770 2.11 1 932
75 12 10 6.90 0.75 0.26 4 276 2.76 3 237
75 6 10 14.38 1.03 0.18 5 306 3.00 4 147
75 6 Lifetime 19.13 1.27 0.22 6 770 3.26 7 340
75 3 Lifetime 38.94 1.56 0.14 9 841 3.40 19 065
80 12 2 1.71 0.23 0.08 1 217 0.75 1 958
80 12 5 3.74 0.46 0.16 2 517 1.30 2 918
80 6 5 7.76 0.60 0.10 2 990 1.42 3 895
80 6 10 12.10 0.88 0.15 4 494 1.78 5 502
80 6 Lifetime 14.09 0.98 0.17 5 122 1.83 15 572
80 3 Lifetime 28.83 1.19 0.11 7 364 1.94 19 402
85 12 2 1.53 0.20 0.07 1 092 0.41 3 112
85 6 2 3.86 0.31 0.05 1 528 0.53 4 118
85 6 5 6.54 0.51 0.09 2 526 0.75 5 404
85 6 10 9.07 0.67 0.12 3 406 0.85 11 558
85 3 10 18.63 0.80 0.07 4 824 0.92 20 914
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to determine the optimal surveillance protocol. This study
also has several limitations.
We did not explicitly model heterogeneity in NMIBC.
Surveillance can be stratiﬁed by pathology ﬁndings, treatment
and recurrence history into low-, intermediate- and high-risk
disease [9]. Individuals with high-grade tumours have a
higher risk of recurrence and progression to MIBC and may
require a more intensive surveillance protocol [5,6]. However,
to reduce the burdens and costs of surveillance, patients at
low-risk of recurrence could follow a less intensive
surveillance strategy [32].
Risk-stratiﬁed surveillance has had slow uptake in the USA,
with evidence of a mismatch between patient-level risk and
intensity of surveillance [33]. The CEFUB cohort, which the
model is based on, did not include the highest-risk minority
of cases with Grade 3 tumours. However, it reﬂects the
majority of incident and prevalent cases, including both
incident and recurrent cases, and is relevant for the subset
where there is lesser consensus in surveillance guidelines. As
such, our present analysis is one of the ﬁrst to apply
modelling to examine these areas of uncertainty, especially
the questions of age, intensity and duration of surveillance.
Whilst the inclusion criteria of the CEFUB trial reﬂected
relatively lower grade, the fact that half of the cohort
included recurrent tumours (with about half of those being
multiply recurrent cases), the risks of progression in that
cohort was nontrivial, higher than might be inferred from
inclusion criteria of Grades 1/2 only. The inclusion in the
present study population of newly diagnosed and recurrent
cases reﬂects a broader spectrum of risk.
Another limitation is that we assumed that all patients with
progression will undergo cystectomy; however, in practice, a
proportion of patients will not undergo cystectomy. This will
impact survival, QoL and costs, but the magnitude is unclear.
Future work will apply the MISCAN model to these
questions. Also, we did not consider adjuvant intravesical
therapies and whilst these adjuncts may reduce risks of
recurrence, implementation in real-world practice is
infrequent [34].
Finally, we did not stratify by gender. Bladder cancer is three-
times more common in men [1], and there is some
uncertainty about the potential for varying recurrence and
progression patterns by sex [35]. Zhang et al. [23] found that
women should be screened more intensively. However,
currently the guidelines do not stratify recommended
surveillance schedules by sex.
Another cost-effective possibility to reduce the number of
cystoscopies might be the utilisation of biomarker tests [e.g.
ﬁbroblast growth factor receptor 3 (FGFR3) mutation
analysis] in voided urine samples [21,36]. A previous analysis
concluded that the effectiveness of surveillance with the
FGFR3 urine test was similar to that of surveillance entirely
by cystoscopy, and the costs were substantially lower. The
utility of such strategies, speciﬁcally amongst older patients
where we found more modest beneﬁts of regular cystoscopy,
warrants further study.
In conclusion, various schedules for surveillance cystoscopy
amongst patients with NMIBC are cost-effective. However,
recognising that bladder cancer has the highest median age at
diagnosis amongst all cancer sites, our present ﬁnding of
modest QALY gains amongst patients aged ≥75 years calls
into question the utility of intensive or lengthy surveillance
schedules amongst this large and growing subset of patients.
Future studies should focus on surveillance stratiﬁed by age
and competing risks, and evaluate the cost and QoL tradeoffs
of innovative urine-based biomarker tests.
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